Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.
about
Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymesPredicting oligonucleotide affinity to nucleic acid targets.Profiled support vector machines for antisense oligonucleotide efficacy predictionNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingAntisense oligonucleotides: treating neurodegeneration at the level of RNASecondary structure and hybridization accessibility of hepatitis C virus 3'-terminal sequences.Aspartyl beta -hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctinAntisense treatment directed against mutated Ki-ras in human colorectal adenocarcinomaNucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase.Determination of optimal sites of antisense oligonucleotide cleavage within TNFalpha mRNA.E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes.Mapping of accessible sites for oligonucleotide hybridization on hepatitis delta virus ribozymesSelection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer.Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes. The most effective ribozymes are not predicted by substrate selection rules.A genomic selection strategy to identify accessible and dimerization blocking targets in the 5'-UTR of HIV-1 RNASerial analysis of mutation spectra (SAMS): a new approach for the determination of mutation spectra of site-specific DNA damage and their sequence dependenceImprovement of RNA secondary structure prediction using RNase H cleavage and randomized oligonucleotides.Native mRNA antisense-accessible sites library for the selection of antisense oligonucleotides, PNAs, and siRNAs.Functional analysis of newly discovered growth control genes: experimental approaches.Controlling the mitochondrial gatekeeper for effective chemotherapy.Prioritized selection of oligodeoxyribonucleotide probes for efficient hybridization to RNA transcriptsA rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structuresVariables and strategies in development of therapeutic post-transcriptional gene silencing agentsRational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation.Solution structure of a purine rich hexaloop hairpin belonging to PGY/MDR1 mRNA and targeted by antisense oligonucleotides.Inhibition of porcine reproductive and respiratory syndrome virus replication in vitro using DNA-based short antisense oligonucleotides.Advances in the development of therapeutic nucleic acids against cervical cancer.In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme.Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides.External guide sequence technology: a path to development of novel antimicrobial therapeutics.Antisense oligonucleotides: from design to therapeutic application.Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I.Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond.Effects of RNA secondary structure on cellular antisense activity.Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.Artificial neural network prediction of antisense oligodeoxynucleotide activityManaging the sequence-specificity of antisense oligonucleotides in drug discovery.Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs.
P2860
Q24527367-68400FDD-1762-4E8C-BEBB-B3671DD9ECB4Q24539440-B0B73FA4-5905-42A7-AB54-197151FFEB8DQ24792682-7E0F6B5F-3E03-4A1D-B275-E5234FAFD8B1Q26825644-9C4B949F-06C5-4CBA-BC9B-1BF39208B7B5Q27007056-CE38D7EB-8C1C-43F4-9818-B0A00F66B7F8Q27472901-2426E793-FD4D-46EC-8218-F3AD357860B3Q28144446-15158998-B4A1-4617-B0FC-0E5F6142F417Q28345950-1305F3AA-4396-4DD9-9838-D083F1769044Q30434521-1F97E556-C39E-4A46-9A64-969970A6ED30Q30662658-F1186BC9-F83B-4924-9BAA-137415467898Q30704352-6FE263A3-0230-4999-B8CF-5533934AD04BQ30732777-0E4156B9-BADA-4B40-ACFC-0A8D663838D5Q30850742-8145A45E-47AF-44CC-B44F-8D39982D85DDQ31142003-4779F301-F7BE-4998-9B03-CC3CEDC1349DQ32030867-B9752B94-6979-4FC9-9538-2BCDD1DFDB1DQ33202244-15884A4A-671D-4A3C-8F63-320E29B9813AQ33371451-94984E93-849A-4BDD-87F3-CDC09806F4DDQ33481558-00E2D022-DCB3-4F3E-9CB5-1D1E48F71197Q33586043-98787049-2271-49EA-A19F-E25290F511B3Q33716358-A7061992-B75D-44BD-A67D-D5EC32F8A63EQ34089134-7A84A36A-5CB9-47CF-A499-02FF8A98B0EBQ34459448-8DB60EE1-6417-4914-A431-4DFCC09D113FQ34646063-89FC1CFD-B269-4D92-AA6A-58F5AF398ED5Q35110219-20ACB880-422F-431D-91F1-278DA61DD13AQ35130605-EF1D59AB-F80B-4FE4-B643-9A3224814138Q35215471-4DA4E44A-1249-46B6-84BD-E03446010827Q35743375-C5F3ACAC-6C8F-4D9E-BAA9-170B8C0BACD7Q35842608-4444F405-D430-4BE2-9B6C-935E9E19AE45Q35904947-7241CFF6-E8AD-456E-BD0E-740FA4ECDDA4Q36048468-A43BDD8B-4171-4E98-8083-6365DA06183AQ36143151-B0185A23-FC14-4E24-9A40-D577BBF6A646Q36478849-59049E59-9D6E-4950-AA7E-EE97C5342795Q38293684-C8D23285-A743-484C-9634-B5490085C517Q38301111-F4DF7E3B-74E2-4454-8C2E-94F089068605Q38303734-BCCE04FC-25A7-474E-84F5-12C1392BB987Q38315200-3B7ADF8B-7CB2-46E5-8BC5-6F6FF473FB1DQ38360555-092CB539-C63B-4D8E-8599-1ED6D6D32D3DQ38362285-108DDB5E-C5D2-4F46-AEFD-E86B2ADEE110Q38828951-ECBFF5BB-4AAC-47D8-8109-C1BA745540DBQ39785439-859B55BE-D06D-48AD-A7D1-22DFD3391307
P2860
Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@ast
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@en
type
label
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@ast
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@en
prefLabel
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@ast
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@en
P2093
P2860
P356
P1476
Potent antisense oligonucleoti ...... ith oligonucleotide libraries.
@en
P2093
Behrens DL
Britton DH
Trainor GL
P2860
P304
P356
10.1093/NAR/24.10.1901
P407
P577
1996-05-01T00:00:00Z